Amgen reported strong Q2 results with significant revenue and earnings growth, and raised its 2014 guidance, indicating confidence in its business. Management highlighted positive progress in its pipeline with several upcoming product launches, and announced a restructuring plan to reduce costs and reallocate resources to high-growth areas. Overall, the positive financial results, increased guidance, and promising pipeline developments suggest a positive short-term impact on the stock price.

[1]